JP4554684B2 - 抗癌治療 - Google Patents

抗癌治療 Download PDF

Info

Publication number
JP4554684B2
JP4554684B2 JP2007538524A JP2007538524A JP4554684B2 JP 4554684 B2 JP4554684 B2 JP 4554684B2 JP 2007538524 A JP2007538524 A JP 2007538524A JP 2007538524 A JP2007538524 A JP 2007538524A JP 4554684 B2 JP4554684 B2 JP 4554684B2
Authority
JP
Japan
Prior art keywords
effective amount
therapeutically effective
pld
formulated
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007538524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008517991A5 (https=
JP2008517991A (ja
Inventor
ジル、エラール
ステルナス、ラルス−アクセル
トリファン、オヴィド
ヴァン・デ・ヴェルデ、ヘルギ
タイテルバウム、エイプリル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Mar SA Unipersonal Soc
Ortho Biotech Products LP
Original Assignee
Pharma Mar SA Unipersonal Soc
Ortho Biotech Products LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4554684(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar SA Unipersonal Soc, Ortho Biotech Products LP filed Critical Pharma Mar SA Unipersonal Soc
Publication of JP2008517991A publication Critical patent/JP2008517991A/ja
Publication of JP2008517991A5 publication Critical patent/JP2008517991A5/ja
Application granted granted Critical
Publication of JP4554684B2 publication Critical patent/JP4554684B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007538524A 2004-10-26 2005-10-26 抗癌治療 Expired - Lifetime JP4554684B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
PCT/GB2005/050189 WO2006046080A2 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009219607A Division JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Publications (3)

Publication Number Publication Date
JP2008517991A JP2008517991A (ja) 2008-05-29
JP2008517991A5 JP2008517991A5 (https=) 2008-11-13
JP4554684B2 true JP4554684B2 (ja) 2010-09-29

Family

ID=36096124

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007538524A Expired - Lifetime JP4554684B2 (ja) 2004-10-26 2005-10-26 抗癌治療
JP2009219607A Pending JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009219607A Pending JP2009292850A (ja) 2004-10-26 2009-09-24 抗癌治療

Country Status (26)

Country Link
US (1) US20090117176A1 (https=)
EP (1) EP1827500B1 (https=)
JP (2) JP4554684B2 (https=)
KR (1) KR101287918B1 (https=)
CN (1) CN101119750B (https=)
AT (1) ATE430586T1 (https=)
AU (1) AU2005298364B2 (https=)
BR (1) BRPI0518250A2 (https=)
CA (1) CA2582452C (https=)
CY (1) CY1110329T1 (https=)
DE (1) DE602005014380D1 (https=)
DK (1) DK1827500T3 (https=)
ES (1) ES2326825T3 (https=)
HR (1) HRP20090345T1 (https=)
IL (1) IL182352A (https=)
MX (1) MX2007004744A (https=)
NO (1) NO328958B1 (https=)
NZ (1) NZ554765A (https=)
PL (1) PL1827500T3 (https=)
PT (1) PT1827500E (https=)
RS (1) RS50822B (https=)
RU (1) RU2359700C2 (https=)
SI (1) SI1827500T1 (https=)
UA (1) UA87877C2 (https=)
WO (1) WO2006046080A2 (https=)
ZA (1) ZA200703396B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1365808B1 (en) * 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN101489593B (zh) 2006-06-19 2015-11-25 约翰·霍普金斯大学 通过脂质体酶的治疗剂肿瘤特异性递送
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
RU2758669C2 (ru) * 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CN1157189C (zh) * 1998-04-06 2004-07-14 伊利诺伊大学评议会 半合成海鞘素
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
EP1365808B1 (en) * 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
EE200300429A (et) * 2001-03-06 2003-12-15 Bristol-Myers Squibb Company Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks
CA2449856C (en) * 2001-06-15 2009-03-10 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
WO2004006755A2 (en) * 2002-07-16 2004-01-22 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) * 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
DE602006020335D1 (de) * 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
PL1827500T3 (pl) 2009-09-30
NO20072543L (no) 2007-07-13
JP2009292850A (ja) 2009-12-17
AU2005298364A1 (en) 2006-05-04
ZA200703396B (en) 2008-11-26
MX2007004744A (es) 2007-10-23
US20090117176A1 (en) 2009-05-07
EP1827500B1 (en) 2009-05-06
RS50822B (sr) 2010-08-31
PT1827500E (pt) 2009-08-05
NZ554765A (en) 2010-01-29
WO2006046080A8 (en) 2007-07-12
KR101287918B1 (ko) 2013-07-19
ES2326825T3 (es) 2009-10-20
DE602005014380D1 (de) 2009-06-18
EP1827500A2 (en) 2007-09-05
CN101119750B (zh) 2013-03-06
CA2582452A1 (en) 2006-05-04
HK1107766A1 (en) 2008-04-18
BRPI0518250A2 (pt) 2008-11-11
CY1110329T1 (el) 2015-01-14
WO2006046080A3 (en) 2006-10-19
UA87877C2 (en) 2009-08-25
ATE430586T1 (de) 2009-05-15
NO328958B1 (no) 2010-06-28
WO2006046080A2 (en) 2006-05-04
CN101119750A (zh) 2008-02-06
JP2008517991A (ja) 2008-05-29
IL182352A0 (en) 2007-07-24
KR20070108135A (ko) 2007-11-08
AU2005298364B2 (en) 2009-03-26
SI1827500T1 (sl) 2009-10-31
RU2359700C2 (ru) 2009-06-27
HRP20090345T1 (en) 2009-08-31
DK1827500T3 (da) 2009-08-31
RU2007119545A (ru) 2008-12-10
CA2582452C (en) 2010-09-07
IL182352A (en) 2016-07-31

Similar Documents

Publication Publication Date Title
JP2009292850A (ja) 抗癌治療
Wu et al. Click activated protodrugs against cancer increase the therapeutic potential of chemotherapy through local capture and activation
TWI724018B (zh) 用於癌症治療之組合療法
RU2498804C2 (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
KR20160023816A (ko) 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
JP2005509599A (ja) 抗癌組み合わせ
CN101123966A (zh) 包含使用et-743和多柔比星来治疗癌症的联合疗法
JP2002507571A (ja) アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物
JP2008536853A (ja) 癌治療のための、組み合わせ、方法および組成物
US10617672B2 (en) Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
TWI469776B (zh) 有助於癌症之治療的方法，組成物以及製品
US20040033271A1 (en) Methods for contemporaneous administration of levamisole and 5-fluorouracil
WO2023062354A2 (en) Nanoparticulate formulation
US20090270340A1 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
JP2022517352A (ja) マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法
HK1107766B (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
JP2003261448A (ja) 抗腫瘍剤
EP4415684A2 (en) Nanoparticulate formulation
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
AU2002225902A1 (en) Methods for contemporaneous administration of levamisole and 5-fluorouracil
HK1182629B (en) Formulations of deoxycholic acid and salts thereof
HK1182629A (en) Formulations of deoxycholic acid and salts thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080828

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080828

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20081023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100615

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100714

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130723

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4554684

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term